12 January 2015
Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces that it has received positive feedback from the US Food and Drug Administration (FDA) on its lead product CT327. Creabilis will now make the final preparations to advance CT327, its novel topical targeted treatment for peripheral pruritus into a pivotal Phase III development program to address pruritus due to psoriasis.
1 December 2014Sequana Medicalís new alfapump technology improves the care of patients with challenging refractory ascites
Technological advances in Sequana Medical’s alfapump system will allow patients and their doctors to better manage the distressing symptoms of refractory ascites, a condition in which fluid builds up in the patient’s abdomen as a result of late-stage liver disease or cancer. With enhanced communications enabled by the new DirectLink Technology, clinicians will now be able to monitor the alfapump remotely.
17 November 2014Wilson Therapeutics announces start of Phase 2 study to evaluate the efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients
Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced the start of a Phase 2 clinical study to evaluate efficacy and safety of its lead product candidate WTX101 in Wilson Disease, a rare genetic disorder and designated orphan disease, in which the body is unable to process copper.
27 October 2014St. Jude Medical Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter - triggering a significant milestone payment to former Endosense shareholders
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its TactiCath™ Quartz irrigated ablation catheter, the company’s newest technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient’s heart wall during an ablation procedure.
8 September 2014
Sonendo®, Inc., the developer of a transformative technology for the endodontic marketplace, announced today it has completed an equity financing totaling $35 million. The proceeds from the financing will be used to further technology development, fund clinical studies, and commercialize Sonendo’s GentleWave™ System for root canal therapy. The System debuted at the American Association of Endodontists (AAE) annual meeting in May of this year, and is currently in limited market release.